fatty diacid is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
The submucosa consists of a layer of dense irregular connective tissue with large blood vessels, lymphatics, and nerves branching into the mucosa and muscular layer. It contains the submucosal plexus, an enteric nervous plexus, situated on the inner surface of the muscularis externa.
== Physiology == A. parasiticus produces aflatoxins B1, B2, G1, and G2, named for the colours emitted under UV light on thin-layer chromatography plates—either blue and green. The numbers refer to the type of compound with 1 being major and 2 being minor. These aflatoxins are carcinogenic mycotoxins which have detrimental effects to humans and livestock. A. parasiticus also has the ability to produce kojic acid, aspergillic acid, nitropropionic acid and aspertoxin as secondary antimicrobial metabolites in response to different environments, all of which can be useful in identification. A. parasiticus also differs in sclerotia quantity number, volume, and shape. This fungus can be reliably identified using molecular methods. A. parasiticus produces aflatoxins at higher concentrations than A. flavus in temperatures ranging from 12–42 °C (54–108 °F) with pH ranging from 3 to greater than 8. Light exposure, oxidative growth conditions, fungal volatiles and nutrient availability (sugars and zinc) affect the production of these toxins. Greater zinc availability increases aflatoxin output. Environmental stress caused by drought and/or high temperatures during the latter part of the growing season of crops increases the likelihood of fungal growth. The aflatoxins produced by A. parasiticus are hazardous under normal food handling conditions and are especially stable when absorbed by starch or protein on the surfaces of seeds.
Ahmad (1990), head team physician of the New York Yankees and professor of Columbia University Vagelos College of Physicians and Surgeons Jennifer Ashton (1991), physician, author, host of lifestyle talk show The Revolution Virginia Cornish (1991), professor of chemistry at Columbia University and recipient of the 2009 Pfizer Award in Enzyme Chemistry Carl Marci (1991), neuroscientist and professor at Harvard Medical School Peter DiMaggio (1992), structural engineer, co-CEO of Thornton Tomasetti Damon Horowitz (1993), Google's in-house philosopher Chris Wiggins (1993), professor of applied mathematics at Columbia University, chief data scientist of The New York Times Rebecca Oppenheimer (1994), curator in astrophysics the American Museum of Natural History Demetre Daskalakis (1995), physician and gay health activist, White House National Monkeypox Response deputy coordinator Laura Kaufman (1997), chemist, professor at Columbia University Beth Willman (1998), astronomer at Haverford College Kate Brauman (2000), water scientist at the University of Minnesota, daughter of chemist John Isaiah Brauman Alex K.
=== Biomechanics === Complications in the diabetic foot and foot-ankle complex are wider and more destructive than expected and may compromise the structure and function of several systems: vascular, nervous, somatosensory, and musculoskeletal. Thus, a deeper comprehension of the alteration of gait and foot biomechanics in the diabetic foot is of great interest and may play a role in the design and onset of preventive as well as therapeutic actions. Briefly, the effect of diabetes on the main structures of the foot-ankle complex can be summarised as:
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known And Loved) and other publications, Alexander Shulgin lists thiobuscaline's dose range as 60 to 120 mg orally and its duration as about 8 hours. Its onset is about 1 hour. The effects of thiobuscaline have been reported to include a "benign and beautiful experience which never quite popped into anything psychedelic", subtle threshold effects, a vague awareness of something, being in a "wonderful place spiritually" but with "some dark edges", it being "pleasant, but certainly not psychedelic", and body discomfort. No clear hallucinogenic effects were described. Thiobuscaline is listed as being 4 times more potent as a psychoactive drug than mescaline. Thiobuscaline produced perpetual threshold psychoactive effects that did not further increase across a wide dose range of 35 to 120 mg orally. Shulgin described it as "always the simple and ephemeral catalyst of euphoria without substance and without body". In addition, he said that it could not easily be classified, for instance as a psychedelic or stimulant. Instead, Shulgin likened thiobuscaline to Ariadne (4C-D), which he noted had been called an "antidepressant". He hypothesized that thiobuscaline might be beneficial for treatment of depression in certain people in the exact same way as Ariadne.
Sources: en.wikipedia.org
BMR (Males) in Kcals/day = 9.99 (weight in kg) + 6.25 (height in cm) – 4.92 (age in years) + 5 BMR (Females) in Kcals/day = 9.99 (weight in kg) + 6.25 (height in cm) – 4.92 (age in years) – 161 The Mifflin St. Jeor Equation has been found to be the most accurate predictor of BMR compared to BMR measured by direct and indirect calorimetry.
High-performance liquid chromatography or high-pressure liquid chromatography is a form of chromatography applying high pressure to drive the solutes through the column faster. This means that the diffusion is limited and the resolution is improved. The most common form is "reversed phase" HPLC, where the column material is hydrophobic. The proteins are eluted by a gradient of increasing amounts of an organic solvent, such as acetonitrile. The proteins elute according to their hydrophobicity. After purification by HPLC the protein is in a solution that only contains volatile compounds, and can easily be lyophilized. HPLC purification frequently results in denaturation of the purified proteins and is thus not applicable to proteins that do not spontaneously refold.
== Use in diagnostic tests == Fecal elastase is an enzyme originally thought to be pancreatic elastase 1 (CELA1), but this was discovered to be an error, and it is actually likely be CELA3B. Fecal elastase is not degraded in intestinal transit, so that its concentration in feces reflects exocrine pancreatic function. In inflammation of the pancreas, fecal elastase is released into the bloodstream. Thus the quantification of fecal elastase in serum allows diagnosis or exclusion of acute pancreatitis. Main indications:
As can be inferred, there is a limited range of molecular weights that can be separated by each column, therefore the size of the pores for the packing should be chosen according to the range of molecular weight of analytes to be separated. For polymer separations the pore sizes should be on the order of the polymers being analyzed. If a sample has a broad molecular weight range it may be necessary to use several GPC columns with varying pores volumes in tandem to resolve the sample fully.
Factors unrelated to the oil's composition are also important, such as the volume of oil utilized, the size of the container, the presence of air currents, and the type and source of light. And practically, even when smoke is cooked in ovens set to above its true smoke point, moisture and other objects can prevent it from reaching the full temperature. The smoke point also decreases over time when oil is reused. Cooks in practice tend to avoid the smoke point by noticing when the oil begins to shimmer, which happens just before it begins to smoke; adding food (to absorb heat) or lowering the temperature will prevent smoking. Acrolein, a potential carcinogen, is often present in the smoke, but this is only an issue to, for example, line cooks burning large quantities of food who breathe in large quantities of smoke over long periods, and not for home cooks. This is because oil chemically decomposes into free fatty acids and glycerol, and at sufficiently high temperatures glycerol with burn to form acrolein. Free radicals produced by the high temperatures, although much reported on, are not dangerous.
Sources: en.wikipedia.org
== Commercialization == There are several liposome medicines currently available commercially, which helps set the regulatory pathway for immunoliposome therapies. As immunoliposome therapy has progressed in research, big market players in pharmaceutical research and manufacturing have invested in the development of these therapies. A relevant example of this is a phase I/II trial that examined the effectiveness of PDS0101 in combination with pembrolizumab, an immune checkpoint inhibitor (sold under the brand name Keytruda). The study is funded by PDS Biotechnology and in partnership with Merck. The purpose of the study is to determine the effectiveness of PDS0101 + pembrolizumab in shrinking tumors in patients with virus-related oropharyngeal cancer tumors in humans. PDS0101 is a peptide-based vaccine that aids in the immune response to kill tumor cells. The study also relies on pembrolizumab monoclonal antibodies to help the body's immune system attack the cancer and interfere with the spread of tumor cells. Although immunoliposome therapy exhibits clinical and commercial promise, there are several known challenges in the translation from laboratory studies to clinical studies and ultimately to commercialization. One obstacle is that immunoliposome therapy is limited by having a short half-life and retention time once it reaches the tumor microenvironment. Additionally, immunoliposome therapies are often individualized which requires close clinical monitoring and comprehensive evaluation methods.
==== Selected reaction monitoring ==== When employing selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) modes, both Q1 and Q3 are set at a specific mass, allowing only a distinct fragment ion from a certain precursor ion to be detected. This method results in increased sensitivity. If Q1 and/or Q3 is set to more than a single mass, this configuration is called multiple reaction monitoring.
SCGJWD Logistics Public Company Limited (SCGJWD; SET: SJWD) was established through a partnership merger between SCG Logistics Management Co., Ltd. (SCGL), a subsidiary of Siam Cement Group, and JWD InfoLogistics (JWD). The share swap transaction was completed on February 14, 2023, and the trading symbol was changed to "SJWD" on February 17, 2023. SCGJWD Logistics Public Company Limited is an integrated logistics service provider with expertise in industrial products, general goods, chemicals, automotive goods and cold chain storage.
== Emerging technologies == Innovation in the food sector may include, for example, new types for raw material processing technology, packaging of products, and new food additives. Applying new solutions may reduce or prevent adverse changes caused by microorganisms, oxidation of food ingredients, and enzymatic and nonenzymatic reactions. Moreover, healthier and more nutritious food may be delivered as well as the food may taste better due to improvements in food composition, including organoleptic changes, and changes in the perception and pleasures from eating food. In the 21st century, emerging technologies such as cellular agriculture, particularly cultured meat, 3D food printing, use of insect protein, plant-based alternatives, vertical farming, food deliveries and blockchain technology are being developed to accelerate the transformation towards sustainable food systems.
The Commission had general powers of administration and was particularly "charged with the duty of arranging for the vote and of taking such measures as it may deem necessary to ensure its freedom, fairness, and secrecy. The Commission will have all necessary authority to decide any questions to which the execution of these provisions may give rise. The Commission will make such arrangements as may be necessary for assistance in the exercise of its functions by officials chosen by itself from the local population. Its decisions will be taken by a majority". The Commission was welcomed by the Poles in the region, who hoped that its presence would improve their situation, but petitions were made to remove German officials and the Sicherheitswehr and demanded the official welcoming committee of German officials to show the representatives of the Allies the plight of ethnic Poles. On 18 February 1919, the Allenstein-based commission decreed that the Polish language would gain equal rights to the German language in the region. The commission eventually had to remove both the mayor of Allenstein, Georg Zülch, and an officer of Sicherheitswehr, Major Oldenburg, after a Polish banner at the local consulate of Poland was defaced. The Poles expressed gratitude for Allied protection of Polish rights and underlined their desire for peaceful co-existence with the Germans. In April 1920, during a Polish theatrical performance in Deuthen (Dajtki), near Allenstein, Poles were attacked by pro-German activists.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.